% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gaasch:309608,
      author       = {A. Gaasch and S. N. Marschner$^*$ and P.
                      Hoegen-Saßmannshausen and E. Sandrini and J. Hörner-Rieber
                      and N. Andratschke and P. Balermpas and L. Boldrini and A.
                      Romano and M. Reiner and M. Niyazi and L. Lindner and L.
                      Weckbach and N. Fink and C. Hagl and C. Belka$^*$ and S.
                      Corradini},
      title        = {{S}tereotactic heart ablative radiotherapy ({SHARP}): a
                      prospective multicentric phase {II} trial.},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {nn},
      issn         = {0179-7158},
      address      = {Heidelberg},
      publisher    = {Springer Medizin},
      reportid     = {DKFZ-2026-00258},
      pages        = {nn},
      year         = {2026},
      note         = {#DKTKZFB9# / epub},
      abstract     = {Cardiac tumors are exceedingly rare with metastatic
                      involvement representing the most frequent form of
                      malignancy within the heart. In patients presenting with
                      inoperable primary or recurrent malignant cardiac sarcomas
                      or cardiac/epicardial/pericardial metastases, stereotactic
                      body radiotherapy (SBRT) serves as an alternative local
                      treatment to surgery or may, in some cases, constitute the
                      sole viable local treatment modality. To date, there are
                      only case reports or small retrospective studies assessing
                      SBRT dose and toxicity for cardiac SBRT. The goal of this
                      prospective multicentric observational study is to
                      systematically evaluate the feasibility, toxicity and
                      outcome of magnetic resonance-guided stereotactic body
                      radiation therapy (MRgSBRT) in the management of primary and
                      secondary cardiac malignancies.The treatment is performed
                      using MR-guided SBRT in five fractions on non-consecutive
                      days (6-8 Gy per fraction prescribed to the $80\%$ isodose).
                      Four study centers participate in this prospective phase II
                      trial (Heidelberg, Munich, Rome, Zurich). Eligible patients
                      who consent to participate in the study will undergo
                      treatment as indicated and approved by an interdisciplinary
                      tumor board. Primary objective is to assess the feasibility
                      and safety of online adaptive MRgSBRT; secondary endpoints
                      are local control and survival outcome, acute and late
                      toxicity, patient-reported outcome as well as technical
                      feasibility of treatment.The findings from this study may
                      serve as a foundation for the future integration of cardiac
                      SBRT into clinical practice guidelines for the management of
                      cardiac malignancies.},
      keywords     = {Cardiac (Other) / MR-guidance (Other) / MRgSBRT (Other) /
                      Online adaptive (Other) / SBRT (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41615458},
      doi          = {10.1007/s00066-026-02504-5},
      url          = {https://inrepo02.dkfz.de/record/309608},
}